Payer reimbursement pressures are leading to radical changes in the oncology treatment, but there is a need for improved guidance for providers in assessing drug value, according to an article in JMCP.
A literature review published in JMCP found mixed evidence regarding the use of pharmacogenomic testing to guide cancer treatment. Prioritization of clinically relevant drug-gene associations is critical in determining which tests are beneficial.
A literature review published in JMCP found mixed evidence regarding the use of pharmacogenomic testing to guide cancer treatment. Prioritization of clinically relevant drug-gene associations is critical in determining which tests are beneficial.
Payer reimbursement pressures are leading to radical changes in the oncology treatment, but there is a need for improved guidance for providers in assessing drug value, according to an article in JMCP.
Partnership Forum: Implementing value-based reimbursement models for both pharmaceuticals and medical care poses significant challenges and opportunities, and depends on integrated delivery networks (IDNs) to execute the processes and programs. Industry thought leaders convened to discuss the issues.
Partnership Forum: AMCP defined the ideal state for PROs , their importance and systems needed in a previous forum. Here AMCP brought together thought leaders to discuss and identify tactics to achieve the “ideal state.”